Mindray Medical Investment Quality Review (300760.SZ)

Quality score: 83/100 Valuation position: current price/base FV 1.58 Final signal: WATCHLIST

Core Conclusion

Mindray Medical is WATCHLIST. Quality is strong, but current price of CNY148.56 is well above conservative/base FV of CNY72.28/CNY94.02, so the valuation gate blocks a BUY signal.

Business And Quality

Five-year revenue CAGR is 7.1% and latest-year FCF is CNY8.11bn. The 83/100 score is supported by medical-device franchise quality, FCF conversion, and net cash; price and evidence depth are the main constraints.

Financial Audit

The review uses fiscal 2021-2025 in CNY. Five-year average FCF/Net Income is 0.91 and OCF/Net Income is 1.12. Latest net cash is CNY17.34bn. Market value is about CNY180.12bn on roughly 1.212bn shares.

Valuation

The valuation uses normalized FCF, a 1.7% CNY 10Y yield dated 2026-07-27, and separate balance-sheet adjustments. Price/base FV of 1.58 fails the 2x gate and leaves no current margin of safety.

Buy And Monitor

Current action is watchlist. Upgrade requires price/base FV below 0.70, quality score at least 75, and stronger evidence that growth, ROIC, and FCF durability remain intact. Track revenue trend, FCF/Net Income, ROIC, net cash/debt, dividends, buybacks, and governance disclosure.

Risks

Risks include procurement pressure, overseas execution, margin compression, weaker FCF conversion, and governance or incentive issues. Two periods with FCF/Net Income below 0.60 would require a valuation reset.

Sources

Sources are public quote and financial data platforms, official filings or company IR, and ChinaBond for the CNY risk-free rate. Research only, not personalized investment advice.